Geron Q4 Earnings Call Highlights

2 weeks ago 13

MarketBeat

Wed, February 25, 2026 astatine 10:03 AM CST 6 min read

Geron logo

Geron Corporation: FDA Approval Fuels Stock Price Surge

Geron (NASDAQ:GERN) absorption utilized its fourth-quarter 2025 net telephone to outline however strategical alignment enactment completed successful 2025 is expected to enactment RYTELO request maturation successful 2026 portion lowering the company’s disbursal basal pursuing a December restructuring.

Chief Executive Officer Harout Semerjian said RYTELO nett gross successful the 4th fourth was $48 million, which helium described arsenic successful enactment with expectations. For the afloat twelvemonth 2025, Geron reported $184 million successful RYTELO nett revenue, which Semerjian called “a meaningful fig for a hematology cause successful its archetypal afloat commercialized year.”

→ Hinge Health’s AI Moat Might Be Its Patient Movement Data

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

For 2026, the institution guided to RYTELO nett gross of $220 cardinal to $240 million, with an presumption of accordant quarter-over-quarter request growth. Chief Financial Officer Michelle Robertson added that Geron expects “a greater information of growth” successful the backmost fractional of the year.

Chief Commercial Officer Ahmed ElNawawi said RYTELO’s 2025 show provides a basal to “further turn request successful 2026.” He highlighted respective fourth-quarter commercialized metrics discussed connected the call, including 9% request growth versus the 3rd 4th and a 13% summation successful prescribing accounts, expanding Geron’s footprint to astir 1,300 accounts. Management besides said first- and second-line diligent starts connected a rolling 12-month ground were astir 30%.

→ Microsoft Is Sliding—An Insider Buy and Oversold Signals Are Changing the Setup

ElNawawi said Geron views marketplace conditions arsenic favorable successful second-line, lower-risk MDS, noting that question of luspatercept into the first-line mounting has “clarified” the second-line accidental for RYTELO. He estimated the eligible second-line, lower-risk MDS diligent colonisation astatine astir 8,000 patients successful the U.S., which helium described arsenic the company’s superior commercialized absorption successful 2026.

Geron framed its 2026 commercialized execution astir 3 halfway initiatives:

Targeted engagement with high-volume assemblage accounts, prioritizing centers treating earlier-line and second-line patients, portion utilizing much integer tactics for lower-volume oregon salvage-focused accounts.
Increased concern successful selling channels the institution считает astir effective, including digital, non-personal promotion, and third-party acquisition platforms—what absorption referred to arsenic a “3D situation sound” approach.
Cross-functional relationship management incorporating ASH 2025 data, including proactive treatment of cytopenias and messaging positioning RYTELO arsenic a standard-of-care enactment for due second-line patients “regardless of their RS status.”